Covid vaccine pause is blow to Oxford Biomedica - The Times

Oxford Biomedica, one of Britain’s leading biotech companies, has warned of lower revenues and losses this year as manufacturing of the Oxford-AstraZeneca coronavirus vaccine is paused and it absorbs the cost of expanding in the United States.In a mixed outlo…

The chairman of Oxford Biomedica emphasised yesterday that it expected to strike a new Covid vaccine supply agreement with AstraZeneca after revealing that manufacturing had been paused. Alongside w… [+559 chars]

full article...